The D.C. Lung Cancer Conference 2026 (DCLung26), held on October 10, 2026, in Washington, D.C., brought together international experts, clinicians, and multidisciplinary specialists to discuss recent advances in lung cancer diagnosis, treatment, and patient care.
The one-day conference focused on the rapidly evolving landscape of thoracic oncology, highlighting developments in lung cancer screening, molecular testing, liquid biopsy, targeted therapies, immunotherapy, and multidisciplinary treatment strategies. The scientific program also addressed the management of early-stage and locally advanced lung cancer, emerging approaches to molecularly defined disease, and treatment considerations for rare thoracic malignancies, including mesothelioma and thymic tumors.
Through expert presentations, clinical case discussions, and interactive sessions, the conference provided an opportunity to examine current evidence, discuss challenges in clinical practice, and explore strategies for improving outcomes for patients with lung cancer.
Here are 15 posts not to miss from DCLung26, highlighting key scientific discussions, expert perspectives, and important developments in lung cancer research and clinical care.
15 Posts Not To Miss From DCLung26
“Deeply grateful for the incredible and truly unmatched friendships in our thoracic oncology community! Feeling blessed, filled up with hugs, smiles, laughter, and encouragements leaving DCLung26.”
“The inaugural DC Lung Prom was a phenomenal success! Kudos to chairs Stephen V. Liu and Joshua Reuss for the incredible celebration & bringing together this wonderful community of amazing thoracic oncology friends! The DCLung26 Prom proceeds support LUNGevity to help provide critical education, fund groundbreaking research, and fuel lung cancer-focused communities built specifically for our patients and their loved ones, including our SCLC SMASHERS.”
“Dr. Noura Choudhury presents the current and projected relapsed/refractory treatment in the evolving landscape for SCLC at DCLung26.”
“Congratulations to Stephen V. Liu and Joshua Reuss for an outstanding and a marvelous first DC Lung Prom!! A day of terrific presentations and insightful conversations. I was honored to present on initial treatment of ES-SCLC! Finished the day by celebrating our amazing lung cancer community with Lung Prom!! All proceeds directly supported LUNGevity Foundation, dedicated to advancing lung cancer research and supporting those affected by the disease.”
“Outstanding talk by Dr. Cecilia Pompili at DCLung26 on the nuances of informed consent. We must meet the patient where they are, ensuring clear communication and mutual understanding of treatment trade offs and goals of care. Terrific reminder while we are discussing ever expanding treatments!”
“Great point by Charu Aggarwal! Not all comprehensive genomic tests are created equal. Different assays, different coverage, different results, with real implications for biomarker detection, patient selection and ultimately treatment decisions. The test you choose matters!”
“Dr. Angel Qin takes us home with a comprehensive overview of treatment approaches for EGFR atypical and exon 20 insertion mutations at DCLung26.”
“Dr. Dwight Owen with a superb summary of immunotherapy combination treatments, both standard and emerging, in advanced NSCLC. Hope to see some advances in this space in near future. DCLung26.”
“Dr. Brendon Stiles discusses the role of surgery in mesothelioma as of 2026. ‘I knew this panel invite was a setup.”
“DCLung26 was not only about learning, but mentoring, too! Great to spend time with Agustina De Rosa, Sylvester Cancer PhD candidate studying EGFR therapy resistance and having the opportunity to introduce her to experts in the field. Grateful to all the colleagues who took the time to share their advice and expertise and encourage the next generation of scientists.”
“Dr. Christian Rolfo covers the comprehensive landscape of novel immunotherapies in lung cancer, from bispecific-/trispecific-T cell engagers, TTF, and bispecific antibodies at DCLung26.”
“Phenomenal talk by Dr. Jennifer Marks at DCLung26 on MET exon 14 skipping NSCLC! Discusses nuances in choosing chemo+ICI vs TKI as initial treatment and future directions including assessing resistance patterns to inform optimal next line of treatment.”
“At DCLung26, Mara Antonoff reviews the evolving role of surgical consolidation in metastatic NSCLC. Where is the evidence strongest? Where do gaps remain? ‘Benefit isn’t one-size fits all. Disease biology and the context of systemic therapy matter.'”
Stay informed with more articles like this on OncoDaily
